---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-235152"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:10:18.901858+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rein Therapeutics receives EMA authorization to begin Phase 2 trial of LTI-03 for IPF

## Summary
- European Medicines Agency approved Phase 2 RENEW trial at clinical sites in Germany and Poland.
- Global randomized, double-blind, placebo-controlled study will enroll up to 120 IPF patients over 24 weeks.
- LTI-03 is a Caveolin-1-derived peptide designed to inhibit fibrosis and support lung tissue regeneration.
- Company previously received UK MHRA clearance; trial will evaluate safety, tolerability, and efficacy.

## SEC filing metadata
- accession: 0001193125-25-235152
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312525235152/0001193125-25-235152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312525235152/d11439d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-235152
- JSON: https://secwatch.observer/filing/0001193125-25-235152.json
- Plain text: https://secwatch.observer/filing/0001193125-25-235152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.